EUVIMEDEUVIMED entdecken
Open Access

Tumefactive demyelination: Clinical outcomes, lesion evolution and treatments

Staley A Brod iD, J William Lindsey, Flavia Nelson

Multiple Sclerosis Journal - Experimental, Translational and Clinical · 2019-04 · 5 (2)

DOI: 10.1177/2055217319855755 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Multiple Sclerosis Journal - Experimental, Translational and Clinical, online erschienen am 18.06.2019. Verfasst von Staley A Brod und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, University of Texas, USA. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Large demyelinating lesions with possible mass effect (tumefactive multiple sclerosis or tumefactive demyelination) can be mistaken for tumour-like space-occupying lesions suggesting a malignant outcome.

Methods

We reviewed our own experience of multiple sclerosis subjects ( n = 28) with tumefactive demyelination to determine the relationship between clinical outcomes and lesion evolution, clinical outcomes and their relationship to different therapies. Patients with central nervous system demyelinating disease were identified from our database over the last 10 years.

Results

No patient increased in extended disability status scale (EDSS). Overall, lesion regression was associated with improved EDSS. Lesion regression was also associated with therapy versus no therapy. No specific therapy or corticosteroid infusions improved EDSS over the long term. The absence of enhancement on follow up on magnetic resonance imaging portended lesion regression.

Conclusion

Tumefactive demyelination may predict a more benign overall course and is susceptible to traditional immunomodulatory treatments.

Schlagwörter

Stichwörter der Autor:innen

Tumefactiveextended disability status scale (EDSS)magnetic resonance imaging (MRI)multiple sclerosis (MS)

Autor:innen und Institutionen

  • Department of Neurology, University of Texas, USA.

ORCID-Profile: Staley A Brod

Zitieren

APA

Brod, S. A., Lindsey, J. W., & Nelson, F. (2019). Tumefactive demyelination: Clinical outcomes, lesion evolution and treatments. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 5(2). https://doi.org/10.1177/2055217319855755

Vancouver

Brod SA, Lindsey JW, Nelson F. Tumefactive demyelination: Clinical outcomes, lesion evolution and treatments. Multiple Sclerosis Journal - Experimental, Translational and Clinical. 2019;5(2). doi:10.1177/2055217319855755

BibTeX
@article{Brod2019,
  author = {Brod, Staley A and Lindsey, J William and Nelson, Flavia},
  title = {Tumefactive demyelination: Clinical outcomes, lesion evolution and treatments},
  journal = {Multiple Sclerosis Journal - Experimental, Translational and Clinical},
  year = {2019},
  volume = {5},
  number = {2},
  doi = {10.1177/2055217319855755}
}
Kostenlos starten →